Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER

References

• Lloyd-Jones D, Adams R, Carnethon M, et al. Heart Disease and Stroke Statistics–2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-181
   PubMed Web of Science ®Google Scholar
• Slejko JF, Sullivan PW. Medical Expenditures Attributable to Coronary Artery Disease in the United States. Value in Health 2009;12:A152-A
   Web of Science ®Google Scholar
• Morbidity and Mortality: 2007. Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, 2007
   Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   Google Scholar
• Ross R. Mechanisms of disease - Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-26
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Levy D, Brezis M, et al. C-Reactive Protein in the Prediction of Cardiovascular Events. N Engl J Med 2003;348:1059-61
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43
   PubMed Web of Science ®Google Scholar
• Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96:24F-33F
   PubMed Web of Science ®Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, et al. Investigators P. Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. JAMA-J Am Med Assoc 2001;286:64-70
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• FDA approves expanded rosuvastatin label. O'Riordan M, Wood S. 2010. Available at: http://www.theheart.org/article/1046095.do [Last accessed 16 Feb 2010]
   Google Scholar
• Costa-Scharplatz M, Ramanathan K, Frial T, et al. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective. Clin Ther 2008;30:1345-57
   PubMed Web of Science ®Google Scholar
• Ohsfeldt RL, Gandhi SK, Fox KM, et al. Statin Cost-Effectiveness Comparisons Using Real-World Effectiveness Data: Formulary Implications. Value in Health 2008;11:1061-9
   PubMed Web of Science ®Google Scholar
• Pignone M, Earnshaw S, Tice JA, et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis. Ann Intern Med 2006;144:326-36
   PubMed Web of Science ®Google Scholar
• Walshe V, Nash A, Barry M. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease. Ir Med J 2006;99:144-5
   PubMedGoogle Scholar
• Bennett K, Kabir Z, Barry M, et al. Cost-Effectiveness of Treatments Reducing Coronary Heart Disease Mortality in Ireland, 2000 to 2010. Value in Health 2009;12:10-5
   PubMed Web of Science ®Google Scholar
• Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation 2007;115:2398-409
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Briggs A, Armitage J, et al. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from randomised trial of 20 536 people. British Medical Journal 2006;333:1145-8A
   PubMed Web of Science ®Google Scholar
• Mullins CD, Rattinger GB, Kuznik A, et al. Cost-Effectiveness of Intensive Atorvastatin Treatment in High-Risk Patients Compared with Usual Care in a Postgeneric Statin Market: Economic Analysis of the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study. Clin Ther 2008;30:2204-16
   PubMed Web of Science ®Google Scholar
• Peura P, Martikainen J, Soini E, et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin 2008;24:1823-32
   PubMed Web of Science ®Google Scholar
• Blake GJ, Ridker PM, Kuntz KM, et al. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am J Med 2003;114:485-94
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels. Circ Cardiovasc Qual Outcomes 2009;2:65-72
   PubMed Web of Science ®Google Scholar
• Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering. Ann Intern Med 2009;150:243-54
   PubMed Web of Science ®Google Scholar
• Nissen SE. The Jupiter trial: Key findings, controversies, and implications. Current Cardiology Reports 2009;11:81-2
   PubMedGoogle Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996
   Google Scholar
• Spatz ES, Canavan, ME, Desai, MM. From Here to JUPITER. Identifying New Patients for Statin Therapy Using Data From the 1999–2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes 2009;2:41-8
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M. An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics 1998;13:397-409
   PubMed Web of Science ®Google Scholar
• Bronnum-Hansen H, Davidsen M, Thorvaldsen P. Long-Term Survival and Causes of Death After Stroke. Stroke 2001;32:2131-6
   PubMed Web of Science ®Google Scholar
• Dennis M, Burn J, Sandercock P, et al. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1993;24:796-800
   PubMed Web of Science ®Google Scholar
• Medical Expenditure Panel Survey (MEPS). Agency for Healthcare Research and Quality(AHRQ). Available at: www.meps.ahrq.gov[Last accessed 3 May 2010]
   Google Scholar
• FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. Food and Drug Administration. 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm204882.htm[Last accessed March 19, 2010]
   Google Scholar
• Law M, Rudnicka AR. Statin Safety: A Systematic Review. The American Journal of Cardiology 2006;97:S52-S60
   PubMed Web of Science ®Google Scholar
• Arias E. United States Life Tables, 2004: Centers for Disease Control and Prevention; 2007
   Google Scholar
• Kendrach MG, Kelly-Freeman M. Approximate Equivalent Rosuvastatin Doses for Temporary Statin Interchange Programs. Ann Pharmacother 2004;38:1286-92
   PubMed Web of Science ®Google Scholar
• Ward S, Jones ML, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:14
   Web of Science ®Google Scholar
• Drugstore.com Online Pharmacy. Available at: http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=00093715656&trx=1Z5066#inf [Last accessed 09 May 2010]
   Google Scholar
• Cherry DK, Woodwell DA, Rechtsteiner EA. National Ambulatory Medicare Care Survey: 2005 Summary. Advance Data From Vital and Health Statistics. Centers for Disease Control and Prevention 2007
   Google Scholar
• American Medical Association. CPT Code/Relative Value Search. 2009. Available at: https://catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp?_requestid=3573 [Last accessed 20 April 2009]
   Google Scholar
• Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality. 2005 Available at: http://www.ahrq.gov/data/hcup/[Last accessed 20 April 2009]
   Google Scholar
• Nawar EW, Niska RW, Xu J. National Hospital Ambulatory Medical Care Survey: 2005 Emergency Department Summary. Advance Data From Vital and Health Statistics Centers for Disease Control and Prevention. 2007
   Google Scholar
• Current Population Survey. Bureau of Labor Statistics. Washington, DC, 2008. Available at: http://www.bls.gov [Last accessed 20 April 2009]
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS). Available at: http://www.cms.hhs.gov/home/medicare.asp [Last accessed 20 April 2009]
   Google Scholar
• Consumer Price Index. Bureau of Labor Statistics. Washington, DC. 2009 Available at: http://www.bls.gov/CPI. [Last accessed: 30 April 2009]
   Google Scholar
• Muennig P. Cost-Effectiveness Analysis in Health. A practical approach. San Francisco: Jossey-Bass., 2008
   Google Scholar
• Heckman J. The common structure of statistical models of truncation, sample selection, and limited dependent variables and a sample estimator for such models. The Annals of Economic and Social Measurement 1976;5:475-92
   Google Scholar
• Heckman J. Sample selection bias as a specification error. Econometrica 1979;47:153-61
   Web of Science ®Google Scholar
• Elixhauser A, Andrews R, Fox S. Clinical Classifications for Health Policy Research: Discharge Statistics by Principal Diagnosis and Procedure. Rockville, MD: Agency for Health Policy and Research 1993
   Google Scholar
• Medicare Provider Analysis and Review of short-stay hospitals. Centers for Medicare and Medicaid Services. 2005. Available at: http://www.cms.hhs.gov/home/medicare.asp [Last accessed 20 April 2009]
   Google Scholar
• Sullivan PW, Ghushchyan V. Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States. Med Decis Making 2006;26:410-20
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Lawrence WF, Ghushchyan V. A National Catalog of Preference-Based Scores for Chronic Conditions in the United States. Medical Care 2005;43:736-49
   PubMed Web of Science ®Google Scholar
• Briggs AH. Handling Uncertainty in Cost-Effectiveness Models. Pharmacoeconomics 2000;17:479-500
   PubMed Web of Science ®Google Scholar
• Briggs A. Advanced Decision Modeling for Health Economic Evaluation. International Society of Pharmacoeconomics and Outcomes Research 13th Annual International Meeting, 2008
   Google Scholar
• Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease. Med Decis Making 2002;22:290-308
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22
   PubMed Web of Science ®Google Scholar
• Slejko JF, Page II RL, Sullivan PW. Statin Therapy is Cost-Effective for Vascular Event Prevention in Adults with Elevated C-Reactive Protein: Implications of Jupiter. J Am Coll Cardiol 2010;55:A131.E1229-A131.E
   Google Scholar
• Slejko JF, Page RL, Sullivan PW. Cost-Effectiveness of Statin Therapy For CHD Prevention in Adults with Elevated C-Reactive Protein: Implications of Jupiter. 31st Annual Meeting of the Society for Medical Decision Making. Hollywood, CA 2009
   Google Scholar
• Simvastatin [package insert]. Whitehouse Station, NJ: Merck Pharmaceuticals 2008
   Google Scholar
• Rosuvastatin [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals 2009
   Google Scholar
• Bates T, Connaughton V, Watts G. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opinion on Pharmacotherapy 2009;10:2973-85
   PubMed Web of Science ®Google Scholar
• Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008;117:1028-36
   PubMed Web of Science ®Google Scholar
• Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Archives of Internal Medicine 2006;166:1842-7
   PubMed Web of Science ®Google Scholar
• Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009;25:567-79
   PubMed Web of Science ®Google Scholar
• New Canadian lipid guidelines will recommend CRP testing for certain patients.Nainggolan L. 2009. Available at: http://www.theheart.org/article/1006911.do[Last accessed Sep 25, 2009]
   Google Scholar
• Michos ED, Blumenthal RS. Prevalence of Low Low-Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S. Implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) Study. J Am Coll Cardiol 2009;53:931-5
   PubMed Web of Science ®Google Scholar